Novartis Discontinues Asthma Drug Development

Date : 12/16/2019 @ 6:54AM
Source : Dow Jones News
Stock : Novartis AG (NVS)
Quote : 96.76  0.47 (0.49%) @ 1:00AM
After Hours
Last Trade
Last $ 96.76 ◊ 0.00 (0.00%)

Novartis Discontinues Asthma Drug Development

Novartis (NYSE:NVS)
Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more Novartis Charts.

By Carlo Martuscelli


Novartis AG (NOVN.EB) said Monday that it will cease development of its investigational asthma drug fevipiprant following disappointing clinical data.

A pooled analysis of the Phase 3 Luster-1 and Luster-2 studies showed that the therapy didn't meet the clinical threshold in the reduction of moderate-to-severe asthma exacerbations when compared with placebo, the company said. The drug was, however, found safe, the Swiss drug maker said.

An analysis of safety and efficacy data from the two studies will be conducted, and details will be published at an upcoming medical conference, Novartis said.


Write to Carlo Martuscelli at; @carlomartu


(END) Dow Jones Newswires

December 16, 2019 01:39 ET (06:39 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest NVS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.